Calogero Pagliarello, Carlo Renè Girardelli, Ignazio Stanganelli
{"title":"爆发性基底细胞癌和来那度胺:皮肤科医生日益提高的认识。","authors":"Calogero Pagliarello, Carlo Renè Girardelli, Ignazio Stanganelli","doi":"10.4081/dr.2022.9534","DOIUrl":null,"url":null,"abstract":"<p><p>Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.</p>","PeriodicalId":11049,"journal":{"name":"Dermatology Reports","volume":"15 1","pages":"9534"},"PeriodicalIF":2.3000,"publicationDate":"2023-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/f8/dr-15-1-9534.PMC10099294.pdf","citationCount":"1","resultStr":"{\"title\":\"Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists.\",\"authors\":\"Calogero Pagliarello, Carlo Renè Girardelli, Ignazio Stanganelli\",\"doi\":\"10.4081/dr.2022.9534\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.</p>\",\"PeriodicalId\":11049,\"journal\":{\"name\":\"Dermatology Reports\",\"volume\":\"15 1\",\"pages\":\"9534\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d7/f8/dr-15-1-9534.PMC10099294.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/dr.2022.9534\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/dr.2022.9534","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists.
Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
